FDA approves Kebilidi as first gene therapy to treat aromatic L-amino acid decarboxylase deficiency
FDA approves Kebilidi as first gene therapy to treat aromatic L-amino acid decarboxylase deficiency
Published: 11/14/2024
Published: 11/14/2024
FDA approves Kebilidi as first gene therapy to treat aromatic L-amino acid decarboxylase deficiency